Company / Gross Margin
10x Genomics, Inc. Gross Margin History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
69.0%
FY2025
5-year range
66.1% / 84.9%
FY2021-FY2025
Trend
+1.8%
vs FY2024
Sector context
#23 of 91
Health Care
What the data says
10x Genomics, Inc.'s gross margin of 69.0% is higher than 75% of companies in the Health Care sector (FY2025). Gross Margin has fluctuated over the past 9 years, ranging from 66.1% in FY2023 to 345.0% in FY2019.
Based on SEC 10-K filings.
69.0% in FY2025 with a 5-year CAGR of -11.4%. Top quartile in the Health Care sector.
Improved from 66.1% to 69.0% over the past 2 years.
Health Care sector context is included.
Gross Margin over time
Growth rates
- 3-Year Change
- -7.6pp
- 5-Year Change
- -11.4pp
- 10-Year Change
- -
Sector benchmark
Top 25% in Health CareTop 25% of 91This company 69.0% Sector average 53.8%
▼
+28.4% above sector average
Key checks
Key Insights
- In FY2025, gross margin increased 1.8% year-over-year.
- Currently 15.3pp above the Health Care sector average.
- Peak gross margin was recorded in FY2019.
- Lowest gross margin in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -29.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 69.0% | +1.8% |
| FY2024 | 67.9% | +2.6% |
| FY2023 | 66.1% | -13.7% |
| FY2022 | 76.7% | -9.7% |
| FY2021 | 84.9% | +5.5% |
| FY2020 | 80.4% | -76.7% |
| FY2019 | 345.0% | +329.1% |
| FY2018 | 80.4% | -5.6% |
| FY2017 | 85.1% | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026